The recommendation, issued under an Article 20 non-pharmacovigilance procedure, places the future of the oral therapy in direct jeopardy. TAVNEOS, developed by ChemoCentryx—now a subsidiary of Amgen—and commercialized internationally by CSL Vifor, is currently used alongside rituximab or cyclophosphamide to manage severe, active forms of granulomatosis with polyangiitis and microscopic polyangiitis.

While the European Commission has yet to issue a final ruling, stakeholders are already bracing for market withdrawal. Dr. Bill Mezzanotte, head of R&D at CSL, acknowledged the disappointment surrounding the decision while confirming the company’s intent to comply with the regulatory process. For the medical community, the immediate concern involves patient safety and treatment continuity. No new patients are being initiated on the therapy in the EU or the European Economic Area, and those currently prescribed the medication are urged to consult their physicians to discuss alternative care paths for their condition.